Regulatory T-cell Therapy in Transplantation: Moving to the Clinic

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2013 Nov 5

PMID 24186492

Citations 121

Authors

Qizhi Tang

Jeffrey A Bluestone

Affiliations

Soon will be listed here.

Abstract

Regulatory T cells (Tregs) are essential to transplantation tolerance and their therapeutic efficacy is well documented in animal models. Moreover, human Tregs can be identified, isolated, and expanded in short-term ex vivo cultures so that a therapeutic product can be manufactured at relevant doses. Treg therapy is being planned at multiple transplant centers around the world. In this article, we review topics critical to effective implementation of Treg therapy in transplantation. We will address issues such as Treg dose, antigen specificity, and adjunct therapies required for transplant tolerance induction. We will summarize technical advances in Treg manufacturing and provide guidelines for identity and purity assurance of Treg products. Clinical trial designs and Treg manufacturing plans that incorporate the most up-to-date scientific understanding in Treg biology will be essential for harnessing the tolerogenic potential of Treg therapy in transplantation.

Citing Articles

Advancing immunosuppression in liver transplantation: the role of regulatory T cells in immune modulation and graft tolerance.

Han J, Park S Clin Transplant Res. 2024; 38(4):257-272.

PMID: 39696994 PMC: 11732766. DOI: 10.4285/ctr.24.0059.

Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment.

Mashayekhi K, Khazaie K, Faubion Jr W, Kim G Bioact Mater. 2024; 37:269-298.

PMID: 38694761 PMC: 11061617. DOI: 10.1016/j.bioactmat.2024.03.030.

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions.

Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R Front Immunol. 2024; 15:1372862.

PMID: 38650942 PMC: 11033354. DOI: 10.3389/fimmu.2024.1372862.

A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models.

Efe O, Gassen R, Morena L, Ganchiku Y, Al Jurdi A, Lape I J Clin Invest. 2024; 134(5).

PMID: 38426492 PMC: 10904054. DOI: 10.1172/JCI173107.

Aberrant NK cell profile in gestational diabetes mellitus with fetal growth restriction.

Xiong Y, Wang Y, Wu M, Chen S, Lei H, Mu H Front Immunol. 2024; 15:1346231.

PMID: 38375483 PMC: 10875967. DOI: 10.3389/fimmu.2024.1346231.

References

Francis R, Feng G, Tha-In T, Lyons I, Wood K, Bushell A . Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol. 2011; 41(3):726-38. PMC: 3175037. DOI: 10.1002/eji.201040509. View

Nadig S, Wieckiewicz J, Wu D, Warnecke G, Zhang W, Luo S . In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010; 16(7):809-13. PMC: 2929438. DOI: 10.1038/nm.2154. View

Berenson G, Wattigney W, Tracy R, Newman 3rd W, Srinivasan S, Webber L . Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol. 1992; 70(9):851-8. DOI: 10.1016/0002-9149(92)90726-f. View

Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S . Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16(8):1189-201. DOI: 10.1093/intimm/dxh122. View

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

Soltys K, Mazariegos G, Squires R, Sindhi R, Anand R . Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant. 2007; 7(9):2165-71. DOI: 10.1111/j.1600-6143.2007.01893.x. View

Gokmen M, Lombardi G, Lechler R . The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol. 2008; 20(5):568-74. DOI: 10.1016/j.coi.2008.06.009. View

Tao R, Hancock W . Regulating regulatory T cells to achieve transplant tolerance. Hepatobiliary Pancreat Dis Int. 2007; 6(4):348-57. View

Posselt A, Szot G, Frassetto L, Masharani U, Tavakol M, Amin R . Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010; 90(12):1595-601. PMC: 4296579. DOI: 10.1097/TP.0b013e3181fe1377. View

10.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

11.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

12.

Bluestone J . The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011; 365(22):2129-31. DOI: 10.1056/NEJMe1110900. View

13.

Dieckmann D, Bruett C, Ploettner H, Lutz M, Schuler G . Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002; 196(2):247-53. PMC: 2193931. DOI: 10.1084/jem.20020642. View

14.

Wise M, Bemelman F, Cobbold S, Waldmann H . Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol. 1998; 161(11):5813-6. View

15.

Kim H, Leonard W . CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med. 2007; 204(7):1543-51. PMC: 2118651. DOI: 10.1084/jem.20070109. View

16.

Rudra D, deRoos P, Chaudhry A, Niec R, Arvey A, Samstein R . Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. 2012; 13(10):1010-9. PMC: 3448012. DOI: 10.1038/ni.2402. View

17.

Long S, Rieck M, Sanda S, Bollyky J, Samuels P, Goland R . Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012; 61(9):2340-8. PMC: 3425404. DOI: 10.2337/db12-0049. View

18.

Morelon E, Lefrancois N, Besson C, Prevautel J, Brunet M, Touraine J . Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol. 2010; 23(1-2):53-8. DOI: 10.1016/j.trim.2010.04.004. View

19.

Ochando J, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F . Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006; 7(6):652-62. DOI: 10.1038/ni1333. View

20.

Meagher C, Tang Q, Fife B, Bour-Jordan H, Wu J, Pardoux C . Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008; 180(12):7793-803. PMC: 2429990. DOI: 10.4049/jimmunol.180.12.7793. View